Bristol Myers Squibb (BMS) announced last week that the National Institute for Health and Care Excellence (NICE) has recommended deucravacitinib, a once-daily oral tablet for use on the NHS in England as an option for treating certain adults with moderate to severe plaque psoriasis.
Learn more about Sotyktu – Summary of Product Characteristics.
Boehringer Ingelheim announced earlier this month that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® (adalimumab), is now commercially available in the United States.
Sandoz announced that Hyrimoz® (adalimumab-adaz) injection is now available in the United States starting July 1.
In this blog post, we examine the findings of a randomized controlled trial investigating the efficacy and safety of oral roflumilast for patients with moderate to severe psoriasis. Discover how this targeted phosphodiesterase-4 inhibitor reduces pro-inflammatory cytokines and improves psoriasis symptoms. Learn about the study’s methodology, key results, and the potential of oral roflumilast as a cost-saving alternative for psoriasis treatment. Find out how this convenient and affordable oral option could benefit patients without access to effective psoriasis therapies.
